Dynamix Pharmaceuticals Completes a $10M Series A Financing
Signs a Collaboration Deal with Teva Pharmaceutical Industries
Dynamix Pharmaceuticals, founded by Dr. Oren M. Becker, who serves as its President and CEO, also announced that it has signed a collaboration and licensing agreement with Teva Pharmaceutical Industries Ltd. for the discovery and development of up to two of Dynamix drug candidates.
Under the terms of the agreement, Dynamix will be eligible to earn milestones based on the achievement of certain discovery, development, regulatory and commercial milestones. Dynamix will also receive tiered royalties on sales by Teva of the collaboration-developed product sales.
Other news from the department business & finance
Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.